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Bone morphogenetic protein type IB receptor is progressively expressed in
malignant glioma tumours
N Yamada', M Kato', P ten Dijkel, H Yamashita', TK Sampath2, C-H Heldin', K Miyazono' and
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Summary The distribution of bone morphogenetic protein (BMP) type I receptors and the activin type I
receptor (ActR-I) was investigated in 16 cases of human glioma and five cases of non-tumorous gliosis tissue by
immunohistochemical technique. Both BMP type IA (BMPR-IA) and the type IB (BMPR-IB) receptors were
detected in human glioma cells. A significant increase in BMPR-IB in tumour cells was observed in malignant
glioma compared with both low-grade astrocytomas (n= 16, P<0.005) and gliosis (n= 13, P<0.001). However,
enhancement of BMPR-IA staining was moderate and ActR-I staining was only weakly expressed in the
malignant glioma tumours. Osteogenic protein (OP)-1/BMP-7, which is known to bind BMPR-IA, BMPR-IB
and ActR-I, was expressed in nervous tissue and was also detected in anaplastic areas of malignant glioma. In
contrast to the tissue materials, BMPR-IA was expressed to a stronger degree than BMPR-IB in human glioma
cell lines; the growth of these cells was suppressed by OP-1. These results suggest the presence of BMP
receptors and a functional role for BMPs in malignant glioma.
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Gliomas are the most common human primary brain
tumours, and are thought to be derived from neuroectoder-
mal glial cells. The most malignant form of the gliomas,
glioblastomas, are thought to be derived from lower grade
astrocytomas through the activation of oncogenes and
inactivation of tumour-suppressor genes (Nigro et al., 1989;
Venter et al., 1991; Collins and James, 1993). Enhanced
expression of platelet-derived growth factor (PDGF) and its
receptors occurs in glioma cells and tissues, suggesting the
presence of autocrine and paracrine growth stimulation
(Nister et al., 1991; Hermanson et al., 1992). Epidermal
growth factor (EGF) receptor genes are frequently amplified,
and found in 40-50% of glioblastomas (Libermann et al.,
1985; Wong et al., 1987).
Bone morphogenetic proteins (BMPs) are a family of
proteins that were originally identified to induce bone and
cartilage formation in ectopic skeletal sites in vivo (Reddi,
1992; Wozney, 1989). More than ten proteins are found to
belong to the BMP family so far, e.g. BMP-2 to -6 (Wozney
et al., 1988; Celeste et al., 1990), osteogenic protein (OP)-1
and -2 (which are also referred to as BMP-7 and -8
respectively) (Ozkaynak et al., 1990, 1992) and growth/
differentiation factor (GDF)-5 to -7 (Storm et al., 1994).
BMPs have various distribution patterns and exert their
biological effects on different cell types. A previous study on
the expression of OP-1 in different mouse tissues (Ozkaynak
et al., 1992) revealed that OP-1 is expressed in kidney, heart
and at a lower level in brain. BMPs stimulate proteoglycan
synthesis in chondroblasts, as well as alkaline phosphatase
activity and collagen synthesis in osteoblasts (Vukicevic et al.,
1989), chemotaxis of monocytes (Cunningham et al., 1992)
and differentiation of neural cells (Paralkar et al., 1992;
Perides et al., 1992, 1993).
BMPs also play important roles in the early stages of
embryogenesis (Lyons et al., 1991; Kingsley, 1994a).
The BMP family of proteins belongs to the transforming
growth factor-0 (TGF-f5) superfamily (ten Dijke et al., 1994a;
Massague et al., 1994; Kingsley, 1994b). The members of the
TGF-fl superfamily exert their effects through complex
formation of two different types of serine/threonine kinase
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receptors, i.e. type I receptors (50-55 kDa) and type II
receptors (70-80 kDa) (ten Dijke et al., 1994a; Massagu& et
al., 1994; Wrana et al., 1994).
Recently, a human BMP type II receptor (BMPR-II) that
binds BMP-4 and OP-I was cloned from a brain cDNA
library (Rozenzweig et al., 1995). Activin type II receptors
(ActRIls) also bind OP-1, but not BMP-4, and transduce
signals (Yamashita et al., 1995). Two human type I receptors,
i.e. activin receptor-like kinase (ALK)-3 (ten Dijke et al.,
1993) and ALK-6 (ten Dijke et al., 1994b), have recently been
shown to bind BMP-4 and OP-l in the presence of type II
receptors, and have therefore been termed BMP receptor type
IA and type IB (BMPR-IA and BMPR-IB) respectively (ten
Dijke et al., 1994c). BMP-4 binds BMPR-IA and BMPR-IB
with equal efficiency, while OP-I binds BMPR-IB more
effectively than BMPR-IA. In addition, OP-1, but not BMP-
4, was shown to bind the activin receptor type I (ActR-I,
formerly termed ALK-2) (ten Dijke et al., 1994c).
Although BMPs are multifunctional proteins, it has not
been fully understood whether BMPs play a role in the
pathogenesis of cancer. Since type I receptors for BMPs are
highly expressed in various parts of the brain (Verschueren et
al., 1995; Dewulf et al., 1995), we investigated the effects of
OP-1, a member of BMP subfamily that is expressed in the
nervous system, on glioma cell lines. Moreover we
investigated the expression of BMPR-IA and -lB as well as
AcR-I in glioma tissues, and compared their expression with
that in non-tumourous tissues.
Materials and methods
Tissue specimens
Formalin-fixed and paraffin-embedded tissue specimens of 16
histopathologically diagnosed gliomas and five cases ofgliosis
were collected from the archives of the Department of
Pathology, University Hospital, Uppsala, Sweden. Tissue
specimens consisted ofeight cases ofglioblastoma multiforme
(GBM), five astrocytomas, two oligoastrocytomas and one
oligodendroglioma as classified according to the WHO
standards (Kleihues et al., 1993). Five specimens with mild
to moderate gliosis derived from patients with epilepsy or
trauma were used as non-neoplastic controls (Table I).
Sections of 3.0,m thickness were cut and collected onExpression of BMP receptors in malignant glioma
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a + +, Frequent occurrence; +, moderate occurrence; ±, rare occurrence; -, no occurrence. b + + +, Strong expression in most cells; + +,
moderate expression in most cells; +, low expression in most cells; ±, low expression in a few cells; -, no expression. GBM, glioblastoma
multiforme; A, astrocytoma; OA, oligoastrocytoma; 0, oligodendroglioma; Pleom., pleomorphism; Mit., mitoticfigure; Nec., centralnecrosis; End.
pl., endothelial proliferation; BMPR-IA, BMP type IA receptor; BMPR-IB, BMP type IB receptor. ActR-I, activin type I receptor.
chromium potassium sulphate gelatin-coated glass slides. One
of the serial sections from each specimen was stained with
haematoxylin-eosin to verify the histopathological diagnosis.
For detection of OP-1, we could not use the tissues, since the
OP-1 antibody failed to work on sections from formalin-fixed
and paraffin-embedded tissues. Therefore, three fresh-frozen
glioblastoma multiforme specimens were taken at the time of
surgery and fixed in acetone at -20°C, until analysed by
immunohistochemistry. They were stained with all four
antibodies.
Preparation of antibodies
Specific rabbit antisera against BMPR-IA, BMPR-IB and
ActR-I were made against synthetic peptides corresponding to
the intracellular juxtamembrane parts of the type I receptors
as described previously (ten Dijke et al., 1994b). Antisera were
affinity purified using CNBr-activated Sepharose CL-4B
(Pharmacia-LKB) columns with immobilised peptides as
described previously (Waltenberger et al., 1993a). A mono-
clonal antibody against recombinant human OP-1 was
generated as described previously (Vukicevic et al., 1994).
Immunohistochemistry
Sections were deparaffinised, rehydrated in descending
alcohol dilutions and immersed in phosphate-buffered saline
(PBS). All slides were treated with 0.001% trypsin (T8003,
Sigma) in PBS for 5 min. ABC peroxidase immunohisto-
chemistry was performed essentially as described previously
(Waltenberger et al., 1993b). The antibodies against BMPR-
IA, BMPR-IB, ActR-I and OP-1 were used at a concentra-
tion of 3 jug ml-'. Tissues were then incubated with
biotinylated goat anti-rabbit IgG (Vector Laboratories,
Burlingame CA, USA), followed by incubation with
Vectastain ABC Elite complex (Vector Laboratories). For
the monoclonal antibody against OP-1, biotinylated anti-
mouse IgG (Vector) was used. The immunoreaction was
visualised by using 3-amino-9-ethylcarbazole (Merck) as a
chromogen in the presence of 0.02% hydrogen peroxide, and
finally counterstained with Mayer's hematoxylin and
mounted in glycerol-gelatin. To exclude the non-specific
reactions of secondary antibodies or ABC complexes,
primary antibody solutions were replaced by I % bovine
serum albumin in PBS. Specificities of the antibodies were
confirmed by blocking the immunohistochemical staining,
after the antibodies had been preincubated with an excess
molar ratio of the corresponding antigens.
Cell culture
Human malignant glioma cell lines, U251MGsp and
U1240MG with fascicular morphology, as well as
U343MGa with fibroblast-like morphology were provided
by Dr Bengt Westermark at the Department of Pathology,
University Hospital, Uppsala, Sweden (Nister et al., 1991).
Mink lung epithelial cells (MvlLu) were obtained from the
American Type Culture Collection (ATCC, Rockville, MD,
USA). All these cell lines were cultured in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 units ml- penicillin, and
50 jig ml-1 streptomycin. Cells were kept in 5% carbon
dioxide humid atmosphere at 37°C.
For immunohistochemistry, these glioma cell lines were
seeded into gelatin-coated Lab-Tek chamber slides (Nunc) at
a density of 1 x 105 cells cm-2. Cells were cultured in DMEM
with 10% FBS until subconfluence was reached. Cells were
rinsed in PBS and fixed in absolute acetone at 4°C for
10 min. The slides were kept at - 70°C until use.
Growth inhibition assay
Mv1Lu cells and the human malignant glioma cell lines were
seeded in 24-well plates at a density of 1 x I04 cells per well
and cultured for 24 h in DMEM with 10% FBS. Then, the
medium was changed to DMEM with 1% FBS containing
various concentrations of recombinant human OP-1
(Sampath et al., 1992). After 16 h of incubation with OP-1,
0.3 jyCi of [3H]thymidine (5.0 Ci mmol-1, Amersham) was
added and the cells were incubated for an additional 2 h. The
cells were then fixed in 5% ice-cold trichloroacetic acid for
1 h and solubilised by incubation with I M sodium hydroxide
for 20 min. The cell extract was neutralised with 1 M
hydrochloric acid, and 3H radioactivity was measured by a
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Statistics
For statistical analysis the specimens were classified into three
groups. An advanced group contained the GBMs. A low-
grade glioma group consisted of five astrocytomas, two
oligoastrocytomas, and one oligodendroglioma. A third
group included five specimens with gliosis classified as non-
tumour cases (Table I). These three groups were compared
with regard to the expression of ActR-I, BMPR-IA and
BMPR-IB receptors. Analyses of variance were carried out
e.t 't.P-* ...
Figure 1 Immunohistochemical staining of BMPR-IA, BMPR-IB and ActR-I. (a) BMPR-IA in a GBM with positive staining on
tumour cells. Vascular cells (V) remain unstained. (b) BMPR-IB in a GBM showing positive immunostaining in the tumour. (c)
ActR-I in a GBM showing positive staining in the tumour cells adjacent to blood vessels (V). (d) OP-I immunostaining in a GBM.
Moderate to strong staining is seen in glioma cells around vascular cells (V). (e) Strong BMPR-IA staining in U343 cells. (f) Weak
staining of BMPR-IB in U343 cells. (g) No staining was seen for ActR-I in U1240 cells. (h) Distinct OP-I immunostaining in U251
cells. (i) a-d, scale bar=30,m; e-h, scale bar=l5,m.
I
I
......using the SuperAnova program. The distribution of scaled
results from the immunohistochemical analysis was normal.
Independent categorical variables used were antigen and
diagnostic groups. The difference between the three groups
(GBM, low-grade and non-tumour) as to expression of BMP
receptors was analysed for each antigen in tumour cells.
Results
Expression of type I receptors for BMP and activin in glioma
tissue
The distribution of BMPR-IA, BMPR-IB and ActR-I in
glioma tissues was examined using immunohistochemical
techniques. Positive immunohistochemical staining for
BMPR-IA was found in the cytoplasm of spindle-shaped
tumour cells surrounding the blood vessels (Figure 1a,
Table I). Strong immunoreactivity for BMPR-IB was found
in the advancing edge of the cell-rich tumour areas (Figure
lb), in gemistocytic and other scattered tumour cells in the
reactive areas. In contrast, astrocytoma, oligoastrocytoma
and gliosis tissues showed weak or no staining (Table I). A
distinct increase of BMPR-IB in tumour cells was observed in
GBM compared with astrocytomas (n = 16, P<0.005), and
with gliosis (n= 13, P<0.001). In contrast, BMPR-IA
staining was moderate and ActR-I staining was only weakly
expressed in some of the GBM tissues (Figure ic). In gliotic
tissues only weak expression of ActR-I or BMPR-I was seen
in a few cases (Table I).
A weakly significant correlation of ActR-I staining with
the degree of malignancy was found when all three groups
were taken together (n=21, P<0.05). Very weak or no
staining was detected in the areas of endothelial proliferation
and extracellular matrix for BMPR-IB and BMPR-IA as well
as for ActR-I. The control tissue sections, where primary
antibodies were omitted, failed to stain positively, excluding
the possibility of non-specific reactions by endogenous
peroxidase, or detection systems. Specificities of the affinity-
purified antibodies as well as the monoclonal OP-1 antibody
were confirmed by nearly complete fading of the stainings
when primary antibodies were blocked with the correspond-
ing antigens.
Expression of OP-I in glioblastoma tissue
OP-1 was also detected in tissue sections of malignant glioma
as revealed by staining with a monoclonal antibody against
human OP-1. In all three glioblastoma multiforme tissues
investigated, moderate staining was observed in the
cytoplasm of glioma cells in high cell density areas (Figure
Id).
Expression of BMP receptors in malignant glioma
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tochemistry. Using the monoclonal antibody against human
OP-1, we found that OP-1 was expressed in all three glioma
cell lines (Table II, Figure Ih). All these cell lines stained
strongly positive by the BMPR-IA antibody (Table II, Figure
le) and weakly by the BMPR-IB antibody (Figure If).
However, no staining was detected by the ActR-I antibody
(Figure Ig). Specificity of the antibodies to BMPR-IA and
BMPR-IB was confirmed by quenching of the staining by
preincubation of the antibodies with the corresponding
peptides (not shown).
Effects of OP-I on the growth ofmalignant glioma cell lines
OP-1 inhibited the growth of malignant glioma cell lines,
U251MGsp, U343MGa and U1240MG as well as that of
MvILu, which was used as comparison; 20-40% inhibition
of [3H]thymidine incorporation was obtained at 10 nM OP-1
(Figure 2).
Discussion
Members of the TGF-,B superfamily have been shown to
inhibit the growth of various cell types (McCarthy and
Bicknell, 1993; Wallen et al., 1989; Matzuk et al., 1992),
however the effect of OP-1 on growth regulation has not been
fully characterised. It has been reported that OP-1 stimulates
the growth of osteoblasts (Sampath et al., 1992), whereas it
inhibits the growth of MvlLu cells (Yamashita et al., 1995).
The growth-inhibitory activities of OP-1 and activin A on
MvlLu cells are approximately 100-fold lower than that of
TGF-,ll (Yamashita et al., 1995). Here, we show that OP-1
inhibits the growth of human malignant glioma cell lines.
Interestingly, these cells are resistant to the growth-inhibitory
action of TGF-,B (Yamada et al., 1995), suggesting that the
signalling pathways for growth inhibition are not entirely
common for OP-1 and TGF-fi.
BMPR-IA is strongly expressed in glioma cell lines,
whereas BMPR-IB is expressed at lower levels. In contrast,
GBM tissues showed moderate to strong expression of
BMPR-IB, and low to moderate expression of BMPR-IA.
Expression of BMPR-Is was weaker in the low-grade
astrocytoma, and very low in gliosis. Thus, a positive
correlation between the malignancy grade of glioma and
the expression of BMPR-IB was observed. On the other
hand, the expression of ActR-I, which binds OP-1 but not
BMP-4 (ten Dijke et al., 1994c), was weak in malignant
gliomas. These results suggest that glioma cells may be more
responsive to the action of BMPs, compared with the cells in
non-tumourous tissues and low-grade gliomas. Moreover, we
showed that one of the ligands for BMPR-Is, i.e. OP-1, is
Expression of BMPR-Is and OP-I in malignant glioma cell
lines
We have previously shown that [1251]-OPi binds to BMPR-
IA, BMPR-IB and ActR-I on U1240MG cells (ten Dijke et
al., 1994b). Although it is difficult to know whether
malignant glioma cell lines represent cells corresponding to
GBM in vivo, expression of OP-1 and type I receptors in
three human glioma cell lines was studied by immunocy-
Table II Expression of OP-1 and its type I receptors in human
malignant glioma cell lines
Cell line BMPR-IA BMPR-IB ActR-I OP-I
U251MGsp + i +
U343MG ++ ± +
U1240MG + ± +
+ +, Moderate expression in most cells; +, low expression in most
cells; ±, low expression in few cells; -, no expression. ActR-I, activin
type I receptor; BMPR-IA, bone morphogenetic protein type IA
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Figure 2 Growth-inhibitory effects of OP-1 on MvlLu cells and
human malignant glioma cell lines were determined by a
[3H]thymidine incorporation assay. Five experiments were done
in triplicate; 20-40% inhibition of [3H]thymidine incorporation
was obtained at 10nM OP-1. MvlLu (---); U251MGsp (-O-);
U343MG (- -); U1240MG (-A-).
4 _%lr F-Expression of BMP receptors in malignant glioma
O" N Yamada et al
628
also expressed in the glioma cells and tissues, suggesting that
autocrine or paracrine control of cellular growth might take
place in the glioma tissues. Northern blot analyses revealed
that BMP-2 to -6 or OP-I to -2 are not expressed in the
normal brain (Sampath et al., 1992). Other members in the
BMP family, e.g. GDF-1 (Lee, 1991) and dorsalin-l (Basler
et al., 1993), are expressed in the normal nervous systems.
The significance of the enhanced expression of OP-1 in the
high-grade glioma for the malignant properties of the cells
remains to be elucidated. Despite the fact that BMPs inhibit
glioma cell growth, it is possible that they contribute to the
malignant phenotype. Thus, BMPs act in the interaction of
epithelial cells and mesenchyma (Lyons et al., 1991), and
stimulate chemotaxis (Cunningham et al., 1992). They can
also induce extracellular matrix and adhesion proteins
(Vukicevic et al., 1989; Paralkar et al., 1992; Perides et al.,
1992, 1993) that are important in the invasive growth of
tumour. Thus, it is possible that BMPs have stimulatory
effects on glioma progression, directly or indirectly, through
these or other mechanisms.
BMPR-II and ActR-IIs, which can function as type II
receptors for BMPs, are expressed in brain (Mathews and
Vale, 1991; Rozenzweig et al., 1995). It remains to be seen
whether they are expressed in glioma. Elucidation of the
functional roles of BMPs in glioma awaits further studies.
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